Nurix Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Nurix Therapeutics Inc in the second quarter 2026?
Nurix Therapeutics Inc recorded a cumulative net loss of $-341 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -76.09%.

Within the Major Pharmaceutical Preparations industry 222 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 63 to 3218.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter	(May 31 2025) II. Quarter
Y / Y Equity Change	-10.05 %	-0 %	2.23 %	-1.22 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-341	-295	-264	-245	-207
Return On Equity (TTM)	-76.09 %	-64.21 %	-57.51 %	-53.57 %	-45.26 %
NRIX's Total Ranking	# 3218	# 63	# 138	# 2934	# 2697
Equity (TTM) in Millions	403	481	539	372	448
Seq. Equity Change	-16.28 %	-10.74 %	44.73 %	-16.83 %	-6.93 %
Seq. Net Income Change	-	-	-	-	-

Back to NRIX Management Effectiveness >> NRIX's 5 Years Annual ROE >> Compare NRIX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 223
Sector	# 488
Overall	# 3218

Return On Equity Statistics
High	Average	Low
-16 %	-52.02 %	-76.09 %
(May 31 2021)		(May 31 2026)

NRIX Annual Return On Equity	(Nov 30 2025) 2025	(Nov 30 2024) 2024	(Nov 30 2023) 2023	(Nov 30 2022) 2022	(Nov 30 2021) 2021
Total Equity in Millions	539	527	200	304	342
Y / Y Equity Change	2.23 %	162.85 %	-33.98 %	-11.28 %	17.93 %
Net Income in Millions	-264	-194	-144	-180	-117
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-49.09 %	-36.73 %	-71.8 %	-59.39 %	-34.24 %

Back to NRIX Management Effectiveness >> NRIX's 5 Years Annual ROE >> Compare NRIX ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NRIX's' Return on Equity at Yahoo Finance
NRIX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NRIX's Competitors
Subscribers only: Roe for Nurix Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NRIX's Customers

Companies with similar Return On Equity at May 31 2026, within Healthcare Sector

ROE

Date modified: 2026-07-10T05:52:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.